Sign In
Buy PCRX
$22.25
-0.710 (-3.09%)
At Close: Jun 02, 2026
-- Poster to be presented at OARSI World Congress on Osteoarthritis -- BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitme
Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again
01:15pm, Monday, 21'st Apr 2025
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History MIAMI , April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital M
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Compan
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
05:00pm, Thursday, 17'th Apr 2025
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan –
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 11'th Apr 2025
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
10:03am, Wednesday, 09'th Apr 2025
PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
12:30pm, Tuesday, 08'th Apr 2025
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
04:30pm, Monday, 07'th Apr 2025
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
10:40am, Friday, 04'th Apr 2025
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind,
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 01'st Apr 2025
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the li
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
01:40pm, Friday, 21'st Mar 2025
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern.
Pacira BioSciences: Back On An Uptrend After Positive Developments
05:27pm, Friday, 14'th Mar 2025
Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeu
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
04:15pm, Friday, 14'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securi
